New developments in multitargeted therapy for patients with solid tumours

Cancer Treatment Reviews

Volumn 34, Issue 1, 2008, Pages 37-48

  Le Tourneau, C ^a   Faivre, S ^a   Raymond, E ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Dasatinib; Imatinib; Multitargeted therapy; Solid tumours; Sorafenib; Sunitinib

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CHIR 258; DASATINIB; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; IMATINIB; IRINOTECAN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NILOTINIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; PLATINUM COMPLEX; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; DYSGEUSIA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; PAIN; PERIPHERAL EDEMA; QT PROLONGATION; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SKIN DISCOLORATION; SOLID TUMOR; STOMATITIS; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; INDOLES; NEOPLASMS; PIPERAZINES; PYRIDINES; PYRIMIDINES; PYRROLES; THIAZOLES;

EID: 38649129787     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.09.003     Document Type: Review

References (72)

1. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 (2005) 172-187
2. Baka S., Clamp A.R., and Jayson G.C. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10 (2006) 867-876
3. Bianco R., Troiani T., Tortora G., and Ciardiello F. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer 12 Suppl. 1 (2005) S159-S171
4. Benjamin L.E., Golijanin D., Itin A., Pode D., and Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103 (1999) 159-165
5. Glade Bender J., Cooney E.M., Kandel J.J., and Yamashiro D.J. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 7 (2004) 289-300
6. Östman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15 (2004) 275-286
7. Potapova O., Laird A.D., Nannini M.A., et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 5 (2006) 1280-1289
8. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
9. Pietras K., Rubin K., Sjöblom T., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62 (2002) 5476-5484
10. Huber P.E., Bischof M., Jenne J., et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65 (2005) 3643-3655
11. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23 (2005) 939-952
12. Gasparini G., Longo R., Fanelli M., and Teicher B.A. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23 (2005) 1295-1311
13. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
14. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
15. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
16. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11 (2005) 4182-4190
17. Von Mehren M., Reichardt P., Casali P.G., et al. A phase I study of nilotinib alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - Study update. Proc Am Soc Clin Oncol 25 18S (2007) 550s [abstract 10023]
18. Dematteo RP, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase II trial ACOSOG Z9001. In: Presented at ASCO annual meeting. Chicago (IL), 2007 [abstract 10079].
19. Marosi C., Vedadinejad M., Haberler C., et al. Imatinib mesylate in the treatment of patients with recurrent high grade gliomas expressing PDGF-R. Proc Am Soc Clin Oncol 24 (2006) 64s [abstract 1526]
20. Dresemann G., Hosius C., Nikolova Z., and Letvak L. Imatinib plus hydroxyurea in pretreated non-progressive glioblastoma (GBM)-A single center phase II study. Proc Am Soc Clin Oncol 24 (2006) 78s [abstract 1583]
21. Heinrich M.C., McArthur G.A., Demetri G.D., et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 24 (2006) 1195-1203
22. Ugurel S., Utikal J., Mohr P., et al. Imatinib in locally advanced dermatofibrosarcoma protuberans (DFSP): A phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Proc Am Soc Clin Oncol 24 (2006) 535s [abstract 9561]
23. Matei D., Emerson R.E., Menning N., et al. Clinical activity of imatinib mesylate in combination with docetaxel in patients with advanced, platinum-resistant ovarian cancer-Hoosier Oncology Group GYN03-62. Proc Am Soc Clin Oncol 24 (2006) 278s [abstract 5091]
24. Srinivas S., Roigas J., Gillessen S., et al. Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results. Proc Am Soc Clin Oncol 25 18S (2007) 244s [abstract 5040]
25. George S., Blay J.Y., Casali P.G., et al. Continuous daily dosing (CDD) of sunitinib malate (SU) compares favourably with intermittent dosing in pts with advanced GIST. Proc Am Soc Clin Oncol 25 18S (2007) 548s [abstract 10015]
26. Brahmer J.R., Govindan R., Novello S., et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study. Proc Am Soc Clin Oncol 25 18S (2007) 395s [abstract 7542]
27. Maki R.G., Fletcher J.A., Heinrich M.C., et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 23 (2005) [abstract 9011]
28. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
29. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
30. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
31. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
32. Escudier B., Koralewski A., Pluzanska A., et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 25 18S (2007) 2s [abstract 3]
33. George D.J., Michaelson M.D., Rosenberg J.E., et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers. Proc Am Soc Clin Oncol 25 18S (2007) 243s [abstract 5035]
34. Miller K.D., Burstein H.J., Elias A.D., et al. Safety and efficacy of sunitinib malate (SU11248) as second-line therapy in metastatic breast cancer (MBC) patients: preliminary results from a Phase II study. Eur J Cancer Suppl 3 (2005) 113 [abstract 406]
35. Lenz HJ, Marshall JL, Rosen LS, et al. Phase II trial of SU11248 in patients with metastatic colorectal cancer (MCRC) after failure of standard chemotherapy. In: Presented at ASCO 2006 gastrointestinal cancers symposium. San Francisco (CA) [abstract 241].
36. Socinski M.A., Sanchez J.M., Novello S., et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial. Proc Am Soc Clin Oncol 24 (2006) 364s [abstract 7001]
37. Kulke M., Lenz H., Meropol N., et al. Results of a phase II study with sunitinib malate (SU11248) in patients (pts) with advanced neuroendocrine tumours (NETs). Eur J Cancer Suppl 3 (2005) 204 [abstract 718]
38. Amato R.J., Harris P., Dalton M., et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). Proc Am Soc Clin Oncol 25 18S (2007) 241s [abstract 5026]
39. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
40. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
41. Escudier B., Szczylik C., Demkow T., et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 24 (2006) [abstract 4501]
42. Ryan C.W., Goldman B.H., Lara P.N., Beer T.M., Drabkin H.A., and Crawford E. Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. Proc Am Soc Clin Oncol 24 (2006) 223s [abstract 4525]
43. Gollob J., Richmond T., Jones J., et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 24 (2006) [abstract 4538]
44. Llovet J., Ricci S., Mazzaferro V., et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). Proc Am Soc Clin Oncol 25 18S (2007) 1s [abstract LBA1]
45. Gatzemeier U., Blumenschein G., Fosella F., et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol 24 (2006) [abstract 7002]
46. Steinbild S., Mross K., Morant D., et al. Phase II study of sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research-EWIV (CESAR). Proc Am Soc Clin Oncol 24 (2006) 144s [abstract 3094]
47. Dahut W.L., Scripture C.D., Posadas E.M., et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. Proc Am Soc Clin Oncol 24 (2006) 218s [abstract 4506]
48. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
49. Hecht J.R., Trarbach T., Jaeger E., et al. A randomized, double-blind, placebo-controlled, phase III study in patients (pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol 23 (2005) [abstract 3]
50. Kohne C., Bajetta E., Lin E., et al. Final results of CONFIRM 2: A multinational randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. Proc Am Soc Clin Oncol 25 18S (2007) 171s [abstract 4033]
51. Major P., Trarbach T., Lenz H., et al. A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. Proc Am Soc Clin Oncol 24 (2006) 153s [abstract 3529]
52. Joensuu H., De Braud F., Coco P., et al. A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. Proc Am Soc Clin Oncol 24 (2006) 527s [abstract 9531]
53. Gauler T.C., Fischer B., Soria J., et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 24 (2006) 412s [abstract 7195]
54. Jahan T.M., Gu L., Wang X., et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). Proc Am Soc Clin Oncol 24 (2006) 384s [abstract 7081]
55. Evans T.R., Morgan J.A., van den Abbeele A.D., et al. Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. Proc Am Soc Clin Oncol 23 (2005) [abstract 3034]
56. Miller K.D., Trigo J.M., Wheeler C., et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11 (2005) 3369-3376
57. Wells S., You Y.N., Lakhani C., et al. A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. Proc Am Soc Clin Oncol 24 (2006) 288s [abstract 5533]
58. Nakagawa K., Kiura K., Shinkai T., et al. A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC. Proc Am Soc Clin Oncol 24 (2006) 380s [abstract 7067]
59. Heymach J.V., Johnson B.E., Prager D., et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Proc Am Soc Clin Oncol 24 (2006) [abstract 7016]
60. Heymach J.V., Paz-Ares L., De Braud F., et al. Randomized phase III study of vandetanib alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 25 18S (2007) 395s [abstract 7544]
61. Rini B., Rixe O., Bukowski R., et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 23 (2005) [abstract 4509]
62. Cohen E.E., Vokes E.E., Rosen L.S., et al. A phase II study of axitinib (AG-013736 [AG]) in patients with advanced thyroid cancers. Proc Am Soc Clin Oncol 25 18S (2007) 301s [abstract 6008]
63. Spano J.L., Chodkiewicz C., Maurel J., et al. A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component. Proc Am Soc Clin Oncol 25 18S (2007) 210s [abstract 4551]
64. Schiller J., Larson T., Ou S.I., et al. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial. Proc Am Soc Clin Oncol 25 18S (2007) 386s [abstract 7507]
65. Rugo H.S., Stopeck A., Joy A.A., et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 25 18S (2007) 32s [abstract 1003]
66. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42 (2006) 1093-1103
67. Heinrich M.C., Maki R.G., Corless C.L., et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. Proc Am Soc Clin Oncol 24 (2006) 520s [abstract 9502]
68. Gray R., Manola J., Saxman S., et al. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res 12 (2006) 1966-1969
69. Le Cesne A., Van Glabbeke M., Verweij J., et al. Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial?. Proc Am Soc Clin Oncol 24 (2006) 522s [abstract 9510]
70. Benjamin R.S., Choi H., Macapinlac H.A., et al. Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression. Proc Am Soc Clin Oncol 24 (2006) 521s [abstract 9506]
71. Rixe O., Meric J., Bloch J., et al. Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 23 (2005) [abstract 3003]
72. Parasuraman S., Hudes G., Levy D., et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of IFN + TEMSR. Proc Am Soc Clin Oncol 25 18S (2007) 247s [abstract 5049]